# Sionna Therapeutics, Inc. (SION)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/sionna-therapeutics-inc/ JSON: https://steadybase.io/company/sionna-therapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 10, 2026.

## Company

- Legal name: Sionna Therapeutics, Inc.
- Ticker: SION (Nasdaq)
- SEC CIK: 0002036042
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Waltham, MA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: sionnatx.com
- Investor relations: https://investors.sionnatx.com/
- LinkedIn: https://www.linkedin.com/company/sionna-therapeutics
- Next earnings date: Feb 4, 2027

## Key facts

- Operating income: -$89.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/0001628280-26-012996-index.html
- Net income: -$75.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/0001628280-26-012996-index.html
- SG&A: $28.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/0001628280-26-012996-index.html
- Employees: 59 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/sionna-20251231.htm
- Shares outstanding: 45,235,568 as of Oct 30, 2026 (10-Q filed Nov 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026072499/0001628280-26-072499-index.html
- Auditor: Deloitte & Touche LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/sionna-20251231.htm

## Business

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to people with CF. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which lead to insufficient CFTR function.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/sionna-20251231.htm

## Officers and directors

- Michael Cloonan, President & CEO. LinkedIn: https://linkedin.com/in/michael-cloonan-74b0bb1. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/2036042/000170433626000005/0001704336-26-000005-index.htm
- Elena Ridloff, CFO and CBO. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/2036042/000177251826000004/0001772518-26-000004-index.htm
- Caroline Stark Beer, Chief Business Officer. Source: Form 4 filed Jan 6, 2026, https://www.sec.gov/Archives/edgar/data/2036042/000208567926000002/0002085679-26-000002-index.htm
- Charlotte McKee, CMO and Head of R&D. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/2036042/000204643326000005/0002046433-26-000005-index.htm
- Jennifer Fitzpatrick, CLO and Head of Program Mgmt.. Source: Form 4 filed Sep 18, 2026, https://www.sec.gov/Archives/edgar/data/2036042/000206185126000009/0002061851-26-000009-index.htm

## Recent 8-K events

- Nov 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026072497/sion-20261110.htm
- Sep 14, 2026: Item 2.05, Costs associated with exit or disposal activities (restructuring); Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm
- Aug 10, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/d135438d8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion-20260806.htm
- Jun 18, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/sion-20260617.htm
- May 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion-20260512.htm
- Mar 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sion-20260302.htm
- Nov 5, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/sion-20251105.htm
- Aug 11, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/sion-20250811.htm
- Jun 13, 2025: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/2036042/000203604225000018/sion-20250612.htm

## Insider trades (Form 4)

- Sep 17, 2026: Rajeev M. Shah (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Sep 17, 2026: Capital Nexus Fund L.P. RA (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Sep 17, 2026: Capital Nexus Fund L.P. RA III (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Sep 17, 2026: Capital Healthcare Fund LP RA (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Sep 17, 2026: Capital Management L.P. Ra (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Sep 17, 2026: Peter Kolchinsky (Director) sold 3,448,811 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000123191926001201/0001231919-26-001201-index.htm
- Jul 7, 2026: Peter A. Thompson (Director) sold 85,918 shares, about $3.9M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000695/0000947871-26-000695-index.htm
- Jul 7, 2026: Advisors Llc Orbimed (Director) sold 85,918 shares, about $3.9M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000694/0000947871-26-000694-index.htm
- Jul 7, 2026: Capital GP VIII LLC OrbiMed (Director) sold 85,918 shares, about $3.9M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000694/0000947871-26-000694-index.htm
- Jul 6, 2026: Jennifer Fitzpatrick (Chief Legal Officer) sold 10,250 shares, about $446,900. Source: https://www.sec.gov/Archives/edgar/data/2036042/000206185126000006/0002061851-26-000006-index.htm
- Jun 30, 2026: Peter A. Thompson (Director) sold 115,844 shares, about $5.3M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000684/0000947871-26-000684-index.htm
- Jun 30, 2026: Capital GP VIII LLC OrbiMed (Director) sold 115,844 shares, about $5.3M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000683/0000947871-26-000683-index.htm
- Jun 30, 2026: Advisors Llc Orbimed (Director) sold 115,844 shares, about $5.3M. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000683/0000947871-26-000683-index.htm
- May 27, 2026: Peter A. Thompson (Director) sold 101 shares, about $4,493. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000588/0000947871-26-000588-index.htm
- May 27, 2026: Advisors Llc Orbimed (Director) sold 101 shares, about $4,493. Source: https://www.sec.gov/Archives/edgar/data/2036042/000094787126000587/0000947871-26-000587-index.htm

## What management said

- "During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination" Mike Cloonan, President and Chief Executive Officer of Sionna (8-K filed Nov 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026072497/sion3q26earningsrelease.htm
- "We continued to advance our clinical NBD1 stabilizer programs during the second quarter as we approach two important clinical milestones this summer" Mike Cloonan, President and Chief Executive Officer of Sionna (8-K filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026053832/sion2q26earningsrelease_fi.htm

## Latest filings

- 8-K filed Sep 14, 2026: https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm
- 10-K filed Mar 2, 2026: https://www.sec.gov/Archives/edgar/data/2036042/000162828026012996/sionna-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/2036042/000162828026053839/sionna-20260630.htm
- DEF 14A filed Apr 27, 2026: https://www.sec.gov/Archives/edgar/data/2036042/000162828026027489/sion-20260427.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

